What is BioScale?
BioScale, through its ProterixBio entity, functions as a high-complexity CLIA-certified laboratory that bridges the gap between advanced scientific research and clinical application. The firm specializes in the development and execution of sophisticated protein assays, most notably the FDA-cleared Presage ST2 Assay, which serves as a vital tool for chronic heart failure prognosis. By offering end-to-end immuno-assay solutions, the company provides essential support to a diverse clientele, including major hospital systems, pharmaceutical giants, and biotech innovators.
The organization's market position is anchored by its ability to deliver high-quality, actionable biomarker data. This capability is supported by a team of experts who manage complex specimen types and therapeutic areas with high efficiency. As the demand for precision medicine and reliable diagnostic testing continues to rise, BioScale remains a critical partner for institutions seeking to improve patient outcomes through data-driven clinical insights.
How much funding has BioScale raised?
BioScale has raised a total of $116.2M across 5 funding rounds:
Series B
$3M
Series C
$20.7M
Series D
$25M
Unspecified
$18.8M
Series A
$48.7M
Series B (2005): $3M, investors not publicly disclosed
Series C (2007): $20.7M led by F2 Ventures and Blackfin Technology
Series D (2010): $25M, investors not publicly disclosed
Unspecified (2013): $18.8M featuring WFD VENTURES, Morningside Group, and New Science Ventures
Series A (2013): $48.7M backed by Morningside Ventures morningside.com and New Science Ventures newscienceventures.com
Key Investors in BioScale
WFD Ventures
A specialized equity firm providing capital and industry expertise to medical device and healthcare technology companies to maximize innovation potential.
Morningside Group
A diversified investment group known for its commitment to high-standard development and long-term value creation across various sectors.
New Science Ventures
A venture capital firm focused on early and late-stage companies that utilize novel scientific approaches to address significant unmet needs in life sciences.
What's next for BioScale?
With the recent influx of capital, BioScale is poised to transition into a more aggressive phase of commercial expansion and technological refinement. The strategic focus will likely center on broadening the utility of its existing biomarker platform and potentially diversifying its diagnostic pipeline to address additional unmet needs in the life sciences sector. By leveraging the expertise of its seasoned investor base, the company is expected to enhance its operational footprint and strengthen its competitive advantage in the diagnostic testing landscape.
Future growth will be driven by the continued integration of its protein assay services into standard clinical workflows. As the company scales, it will likely prioritize the optimization of its laboratory processes to maintain high-throughput capabilities while upholding the rigorous standards required for clinical-grade diagnostic reporting. This strategic roadmap positions BioScale to capitalize on the increasing reliance on biomarker-based prognosis in modern healthcare.
